CORBION N.V. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 19.28 EUR | +3.49% |
|
+2.06% | -0.52% |
| 04-17 | Evotec Names First Chief People Officer | MT |
| 04-12 | Corbion Appoints Barry Callebaut Chief Human Resources Officer to Same Role | MT |
Strengths
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The group shows a rather high level of debt in proportion to its EBITDA.
- The company is highly valued given the cash flows generated by its activity.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Specialty Chemicals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -0.52% | 1.22B | B+ | ||
| +11.47% | 63.22B | A- | ||
| -3.47% | 46.34B | A- | ||
| +13.72% | 39.97B | B+ | ||
| +17.83% | 25.46B | A- | ||
| +7.27% | 18.68B | C+ | ||
| -0.57% | 17.24B | B+ | ||
| -21.73% | 15.81B | A- | ||
| +0.22% | 14.9B | B+ | ||
| -19.10% | 13.74B | C+ |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- CRBN Stock
- Ratings Corbion N.V.
